Albert Garcia‐Romeu

5.4k total citations · 3 hit papers
73 papers, 3.4k citations indexed

About

Albert Garcia‐Romeu is a scholar working on Clinical Psychology, Organic Chemistry and Cellular and Molecular Neuroscience. According to data from OpenAlex, Albert Garcia‐Romeu has authored 73 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Clinical Psychology, 32 papers in Organic Chemistry and 19 papers in Cellular and Molecular Neuroscience. Recurrent topics in Albert Garcia‐Romeu's work include Psychedelics and Drug Studies (49 papers), Chemical synthesis and alkaloids (32 papers) and Neurotransmitter Receptor Influence on Behavior (19 papers). Albert Garcia‐Romeu is often cited by papers focused on Psychedelics and Drug Studies (49 papers), Chemical synthesis and alkaloids (32 papers) and Neurotransmitter Receptor Influence on Behavior (19 papers). Albert Garcia‐Romeu collaborates with scholars based in United States, Canada and United Kingdom. Albert Garcia‐Romeu's co-authors include Matthew W. Johnson, Roland R. Griffiths, Mary P Cosimano, William A. Richards, Kelly E. Dunn, Alan K. Davis, Peter H. Addy, Fire Erowid, Earth Erowid and Tehseen Noorani and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Albert Garcia‐Romeu

67 papers receiving 3.3k citations

Hit Papers

Pilot study of the 5-HT2AR agonist psilocybin in the trea... 2014 2026 2018 2022 2014 2016 2015 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
    2014 666 citations Matthew W. Johnson, Albert Garcia‐Romeu et al. Journal of Psychopharmacology profile →
  2. Long-term follow-up of psilocybin-facilitated smoking cessation
    2016 440 citations Matthew W. Johnson, Albert Garcia‐Romeu et al. profile →
  3. Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction
    2015 356 citations Albert Garcia‐Romeu, Roland R. Griffiths et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Albert Garcia‐Romeu United States 27 2.8k 1.9k 1.3k 463 431 73 3.4k
Kim P. C. Kuypers Netherlands 39 2.9k 1.0× 1.3k 0.7× 1.7k 1.3× 439 0.9× 1.1k 2.5× 127 4.3k
Adam L. Halberstadt United States 37 3.4k 1.2× 1.8k 1.0× 2.6k 2.1× 595 1.3× 395 0.9× 90 4.6k
John H. Halpern United States 23 1.3k 0.5× 674 0.4× 814 0.6× 232 0.5× 453 1.1× 38 2.3k
Alan K. Davis United States 31 3.6k 1.3× 2.0k 1.1× 1.5k 1.2× 471 1.0× 577 1.3× 112 4.4k
Jordi Riba Spain 47 4.7k 1.6× 1.8k 0.9× 2.4k 1.9× 1.6k 3.6× 1.1k 2.6× 92 6.4k
Rick J. Strassman United States 29 2.8k 1.0× 1.2k 0.6× 1.5k 1.2× 690 1.5× 881 2.0× 52 3.8k
Rafael G. dos Santos Brazil 33 3.1k 1.1× 1.3k 0.7× 1.3k 1.1× 1.2k 2.5× 1000 2.3× 100 3.8k
Dennis J. McKenna United States 25 1.5k 0.5× 498 0.3× 957 0.8× 529 1.1× 587 1.4× 44 2.7k
Katherine A. MacLean United States 22 2.5k 0.9× 868 0.5× 723 0.6× 268 0.6× 192 0.4× 30 3.4k
Natasha L. Mason Netherlands 26 1.8k 0.6× 1.0k 0.5× 977 0.8× 376 0.8× 343 0.8× 73 2.2k

Countries citing papers authored by Albert Garcia‐Romeu

Since Specialization
Citations

This map shows the geographic impact of Albert Garcia‐Romeu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Garcia‐Romeu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Garcia‐Romeu more than expected).

Fields of papers citing papers by Albert Garcia‐Romeu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert Garcia‐Romeu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Garcia‐Romeu. The network helps show where Albert Garcia‐Romeu may publish in the future.

Co-authorship network of co-authors of Albert Garcia‐Romeu

This figure shows the co-authorship network connecting the top 25 collaborators of Albert Garcia‐Romeu. A scholar is included among the top collaborators of Albert Garcia‐Romeu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Garcia‐Romeu. Albert Garcia‐Romeu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lodovico, Laura Di, Mikaïl Nourredine, Francesco Salvo, et al.. (2025). Impact of psychedelics on craving in addiction: A systematic review. Journal of Psychopharmacology. 4116357573–4116357573. 2 indexed citations
2.
Mathai, David S., Sandeep M. Nayak, Nathan D. Sepeda, et al.. (2025). Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World Psilocybin Use. Journal of Psychoactive Drugs. 1–12. 3 indexed citations
3.
4.
5.
6.
Strickland, Justin C., Albert Garcia‐Romeu, & Matthew W. Johnson. (2024). The Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item. PubMed. 2(1). 33–43. 5 indexed citations
7.
8.
Mathai, David S., et al.. (2024). Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals. Scientific Reports. 14(1). 28022–28022. 7 indexed citations
9.
10.
Steinberg, Martin, Paul B. Rosenberg, & Albert Garcia‐Romeu. (2023). The Potential for Psychedelics to Improve Coping Skills and Resilience in Persons With Newly Diagnosed Mild Cognitive Impairment or Early Alzheimer’s Disease. Current Geriatrics Reports. 12(3). 149–155. 1 indexed citations
11.
Mathai, David S., Sandeep M. Nayak, David B. Yaden, & Albert Garcia‐Romeu. (2023). Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine. Psychopharmacology. 240(4). 827–836. 25 indexed citations
12.
Smith, Kirsten E., Kelly E. Dunn, Jeffrey M. Rogers, et al.. (2022). Assessment of Kratom Use Disorder and Withdrawal Among an Online Convenience Sample of US Adults. Journal of Addiction Medicine. 16(6). 666–670. 29 indexed citations
13.
Mathai, David S., Andrew G. Guzick, Sophie C. Schneider, et al.. (2021). Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality. Journal of Child and Adolescent Psychopharmacology. 31(8). 553–561. 12 indexed citations
14.
Garcia‐Romeu, Albert, Frederick S. Barrett, Theresa M. Carbonaro, Matthew W. Johnson, & Roland R. Griffiths. (2021). Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. Journal of Psychopharmacology. 35(4). 353–361. 70 indexed citations
15.
Yaden, David B., et al.. (2021). Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. International Journal of Drug Policy. 98. 103380–103380. 34 indexed citations
16.
Garcia‐Romeu, Albert, et al.. (2021). Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms. Current topics in behavioral neurosciences. 56. 287–317. 26 indexed citations
17.
Smith, Kirsten E., Kelly E. Dunn, Oliver Grundmann, et al.. (2021). Social, psychological, and substance use characteristics of U.S. adults who use kratom: Initial findings from an online, crowdsourced study.. Experimental and Clinical Psychopharmacology. 30(6). 983–996. 35 indexed citations
18.
Henningfield, Jack E., Sherecce Fields, James C. Anthony, et al.. (2020). Advancing equity, diversity, and inclusion in the American College of Neuropsychopharmacology (ACNP): advances, challenges, and opportunities to accelerate progress. Neuropsychopharmacology. 46(5). 871–876. 7 indexed citations
19.
Noorani, Tehseen, Albert Garcia‐Romeu, Thomas Cody Swift, Roland R. Griffiths, & Matthew W. Johnson. (2018). Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. Journal of Psychopharmacology. 32(7). 756–769. 181 indexed citations
20.
Garcia‐Romeu, Albert, Roland R. Griffiths, & Matthew W. Johnson. (2017). Psychedelic-associated addiction remission: An online survey. Drug and Alcohol Dependence. 171. e69–e69. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kim P. C. Kuypers Breakdown of academic impact, for papers by Adam L. Halberstadt Breakdown of academic impact, for papers by John H. Halpern Breakdown of academic impact, for papers by Alan K. Davis Breakdown of academic impact, for papers by Jordi Riba Breakdown of academic impact, for papers by Rick J. Strassman Breakdown of academic impact, for papers by Rafael G. dos Santos Breakdown of academic impact, for papers by Dennis J. McKenna Breakdown of academic impact, for papers by Katherine A. MacLean Breakdown of academic impact, for papers by Natasha L. Mason
Rankless by CCL
2026